Key statistics
As of last trade, Verrica Pharmaceuticals Inc (1NE:FRA) traded at 0.762, 18.51% above the 52 week low of 0.643 set on Nov 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.762 |
---|---|
High | 0.762 |
Low | 0.762 |
Bid | 0.763 |
Offer | 0.794 |
Previous close | 0.643 |
Average volume | 4.16k |
---|---|
Shares outstanding | 42.67m |
Free float | 20.95m |
P/E (TTM) | -- |
Market cap | 35.41m USD |
EPS (TTM) | -1.83 USD |
Data delayed at least 15 minutes, as of Nov 11 2024 07:30 GMT.
More ▼
- Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition
- Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
- Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
- Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
- Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
- Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma
- Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024
- Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
- Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
- Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
More ▼